©2024 Stanford Medicine
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
Not Recruiting
Trial ID: NCT00568308
Purpose
The purpose of this study is to determine if PI-88 is effective and safe in patients who have
had surgery to remove primary liver cancer.
Official Title
A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma
Stanford Investigator(s)
Samuel So, MD
Lui Hac Minh Professor in the School of Medicine
Eligibility
Key Inclusion Criteria:
- Histologically-proven primary hepatocellular carcinoma with curative resection
performed in the 4 - 6 weeks prior to randomisation.
- ECOG performance status 0 to 2
- Child Pugh classification A or B
Key Exclusion Criteria:
- Any evidence of tumour metastasis or co-existing malignant disease
- Any prior recurrence of HCC or any liver resection prior to the most recent procedure
- History of prior HCC therapy
Intervention(s):
drug: placebo
drug: PI-88
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kerry Hsieh
6507247245